Indication

In combination with pembrolizumab for the first‑line treatment of advanced renal cell carcinoma in adults

Medicine details

Medicine name:
lenvatinib (Kisplyx)
SMC ID:
SMC2476
Pharmaceutical company
Eisai Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Publication due date:
13 June 2022